Khiron Life Sciences has received 2020 commercial cultivation quotas from the Colombian Technical Quotas Group, to cultivate psychoactive cannabis plants for national and export commercial purposes in 2020 utilizing the previously announced 22 strains already registered with the ICA's National Cultivar Registry.
"We are very satisfied to have been awarded 17% of Colombia`s total production quota for 2020. This continues to demonstrate our regulatory expertise and the trust that the Government of Colombia, and the Ministry of Justice has on our business plan. For the last 3 years, Khiron has been a leader in Colombia by driving regulatory milestones which place the Company on a path to imminent sales of medical cannabis in Colombia and improving the lives of million of patients in the country, Latin America, and Europe." Comments Alvaro Torres, CEO Khiron Life Sciences Corp.
"With a Q3 cash balance of $47.9 million and all facilities complete, we are ready to begin cultivation activities immediately."
For more information:
Khiron Life Sciences Corp.
khiron.ca